PubMed:27003763 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":76},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":77,"end":120},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":121,"end":131},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":132,"end":244},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":245,"end":253},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":254,"end":382},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":383,"end":461},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":462,"end":517},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":518,"end":526},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":527,"end":650},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":651,"end":759},"obj":"Sentence"},{"id":"TextSentencer_T12","span":{"begin":760,"end":824},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":76},"obj":"Sentence"},{"id":"T2","span":{"begin":77,"end":120},"obj":"Sentence"},{"id":"T3","span":{"begin":121,"end":131},"obj":"Sentence"},{"id":"T4","span":{"begin":132,"end":244},"obj":"Sentence"},{"id":"T5","span":{"begin":245,"end":253},"obj":"Sentence"},{"id":"T6","span":{"begin":254,"end":382},"obj":"Sentence"},{"id":"T7","span":{"begin":383,"end":461},"obj":"Sentence"},{"id":"T8","span":{"begin":462,"end":517},"obj":"Sentence"},{"id":"T9","span":{"begin":518,"end":526},"obj":"Sentence"},{"id":"T10","span":{"begin":527,"end":650},"obj":"Sentence"},{"id":"T11","span":{"begin":651,"end":759},"obj":"Sentence"},{"id":"T12","span":{"begin":760,"end":824},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: A double-blind, randomized, clinical trial.\nOBJECTIVE: This study aimed to estimate the effectiveness of L-arginine for preventing preeclampsia in high-risk pregnancy.\nMETHODS: We performed a randomized, double-blind, placebo-controlled, clinical trial in patients with high-risk factors for preeclampsia. Fifty subjects received L-arginine, beginning from the 20th week of gestation. An additional 50 patients received homologated placebo.\nRESULTS: The placebo group had a higher number of cases of preeclampsia (11/47) compared with the L-arginine group (3/49, P = 0.01). Birth weight was higher in the L-arginine group and there was a smaller number of preterm births (P = 0.03).\nCONCLUSION: L-arginine is effective for preventing preeclampsia."}

{"project":"Preeclampsia","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":38,"end":50},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":208,"end":220},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":369,"end":381},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":577,"end":589},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T5","span":{"begin":811,"end":823},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: A double-blind, randomized, clinical trial.\nOBJECTIVE: This study aimed to estimate the effectiveness of L-arginine for preventing preeclampsia in high-risk pregnancy.\nMETHODS: We performed a randomized, double-blind, placebo-controlled, clinical trial in patients with high-risk factors for preeclampsia. Fifty subjects received L-arginine, beginning from the 20th week of gestation. An additional 50 patients received homologated placebo.\nRESULTS: The placebo group had a higher number of cases of preeclampsia (11/47) compared with the L-arginine group (3/49, P = 0.01). Birth weight was higher in the L-arginine group and there was a smaller number of preterm births (P = 0.03).\nCONCLUSION: L-arginine is effective for preventing preeclampsia."}

{"project":"Preeclampsia-compare","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":38,"end":50},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":208,"end":220},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":369,"end":381},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":577,"end":589},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T5","span":{"begin":811,"end":823},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: A double-blind, randomized, clinical trial.\nOBJECTIVE: This study aimed to estimate the effectiveness of L-arginine for preventing preeclampsia in high-risk pregnancy.\nMETHODS: We performed a randomized, double-blind, placebo-controlled, clinical trial in patients with high-risk factors for preeclampsia. Fifty subjects received L-arginine, beginning from the 20th week of gestation. An additional 50 patients received homologated placebo.\nRESULTS: The placebo group had a higher number of cases of preeclampsia (11/47) compared with the L-arginine group (3/49, P = 0.01). Birth weight was higher in the L-arginine group and there was a smaller number of preterm births (P = 0.03).\nCONCLUSION: L-arginine is effective for preventing preeclampsia."}

{"project":"yangbin123xm_800_3","denotations":[{"id":"T1","span":{"begin":12,"end":22},"obj":"CI"},{"id":"T12","span":{"begin":509,"end":516},"obj":"CI"},{"id":"T14","span":{"begin":531,"end":538},"obj":"CI"},{"id":"T2","span":{"begin":182,"end":192},"obj":"CI"},{"id":"T3","span":{"begin":407,"end":417},"obj":"CI"},{"id":"T4","span":{"begin":616,"end":626},"obj":"CI"},{"id":"T5","span":{"begin":682,"end":692},"obj":"CI"},{"id":"T6","span":{"begin":772,"end":782},"obj":"CI"}],"text":"Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: A double-blind, randomized, clinical trial.\nOBJECTIVE: This study aimed to estimate the effectiveness of L-arginine for preventing preeclampsia in high-risk pregnancy.\nMETHODS: We performed a randomized, double-blind, placebo-controlled, clinical trial in patients with high-risk factors for preeclampsia. Fifty subjects received L-arginine, beginning from the 20th week of gestation. An additional 50 patients received homologated placebo.\nRESULTS: The placebo group had a higher number of cases of preeclampsia (11/47) compared with the L-arginine group (3/49, P = 0.01). Birth weight was higher in the L-arginine group and there was a smaller number of preterm births (P = 0.03).\nCONCLUSION: L-arginine is effective for preventing preeclampsia."}

{"project":"chenxin_473849_800_3","denotations":[{"id":"T1","span":{"begin":12,"end":22},"obj":"CI"},{"id":"T2","span":{"begin":182,"end":192},"obj":"CI"},{"id":"T3","span":{"begin":407,"end":417},"obj":"CI"},{"id":"T4","span":{"begin":616,"end":626},"obj":"CI"},{"id":"T5","span":{"begin":682,"end":692},"obj":"CI"},{"id":"T6","span":{"begin":772,"end":782},"obj":"CI"},{"id":"T8","span":{"begin":531,"end":538},"obj":"CI"},{"id":"T9","span":{"begin":509,"end":516},"obj":"CI"}],"text":"Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: A double-blind, randomized, clinical trial.\nOBJECTIVE: This study aimed to estimate the effectiveness of L-arginine for preventing preeclampsia in high-risk pregnancy.\nMETHODS: We performed a randomized, double-blind, placebo-controlled, clinical trial in patients with high-risk factors for preeclampsia. Fifty subjects received L-arginine, beginning from the 20th week of gestation. An additional 50 patients received homologated placebo.\nRESULTS: The placebo group had a higher number of cases of preeclampsia (11/47) compared with the L-arginine group (3/49, P = 0.01). Birth weight was higher in the L-arginine group and there was a smaller number of preterm births (P = 0.03).\nCONCLUSION: L-arginine is effective for preventing preeclampsia."}